Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% for a specific cohort of a ...

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

Results presented at the European Society for Medical Oncology meeting could help separate Roche’s medicine from similar ...

Isabel Casimiro, MD, PhD, is an endocrinologist at the University of Chicago in Illinois. As a physician-scientist in molecular biology, she uses her research on diabetes, lipid disorders, ...